top of page
Biogenera
Develops drugs targeting the mutated DNA that causes serious diseases, with a particular focus on paediatric tumours. Using its proprietary MyGenera™ platform, the company rapidly identifies and designs ultra-specific therapies tailored to each patient. This revolutionary approach opens up new prospects for treating hitherto incurable pathologies.
PSCC's entrance
Décembre 2025
Localization
IT - Bologna
Modality
Cell & Gene therapy
Development status
Biotech - Pre-IND/Pre-CTA
Lauréat (s)
bottom of page



